BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Scientists Trip Over Potential Breakthrough in Dementia Research

  A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.

  May 10, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Business

  ADC, Adimab and Longeveron Begin New Leadership Chapters

  Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.

  May 10, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  MOMA is Raging Against the Machine with $150M in New Funds

  MOMA stated that it plans to use the money to further develop product opportunities and advance a rich pipeline of precision oncology programs.

  May 10, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Eisai, Biogen Take Another Step Toward Potential Approval of Alzheimer’s Drug Lecanemab

  Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.

  May 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Astellas, Twist Join Forces to Enhance Tumor Immunity

  Twist Bioscience and Astellas Pharma have entered into a collaboration to identify therapeutic antibodies to reduce tumor microenvironment-mediated immunosuppression.

  May 10, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Idorsia Abandons Binge Eating Indication Following Phase II Trial Failure

  Idorsia is no longer continuing research into the use of ACT-539313 to treat binge eating disorders after failing to meet the primary endpoint in its latest trial.

  May 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Drug Development

  Novavax’s First Profitable Commercial Quarter Marred by Slow Vaccine Rollout

  Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.

  May 10, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  BMS Adds Potential $5B to Evotec Protein Degrader Partnership

  Bristol Myers Squibb announced it is extending and expanding its strategic partnership with Evotec in targeted protein degradation, marking its second protein degradation deal this month.

  May 10, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Deals

  Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven

  Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.

  May 10, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Cash-Rich CRISPR Therapeutics Expects Year Filled with Milestones

  CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.

  May 10, 2022

   · 

  4 min read

   · 

  Mark Terry